Jonie Ing Kondracki

Cooley advised Instacart, the leading grocery technology company in North America, on its $660 million initial public offering.

Cooley advised the underwriters on Ascendis Pharma’s $460 million follow-on offering. J.P. Morgan Securities, Morgan Stanley, Evercore Group, and SVB Leerink acted as joint book-running managers for the offering. Ascendis is a biopharmaceutical company applying its TransCon technologies to create new and potentially best-in-class therapies. Partners Jonie Kondracki, Charlie Kim, and Div Gupta led the Cooley team representing the underwriters.

Cooley advised LegalZoom.com, Inc. on its initial public offering of 21,989,150 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $28.00 per share, and the concurrent sale of 3,214,285 additional shares of common stock in a private placement at the public offering price of $28.00 per share – for aggregate gross proceeds totaling $705.7 million. LegalZoom.com, whose securities now trade on the Nasdaq Global Select Market under the symbol “LZ,” is a leading online platform for legal and compliance solutions in the United States. Partners Tom Hopkins, Jodie Bourdet and Jonie Ing Kondracki led the Cooley team advising LegalZoom.

Cooley advised the underwriters on Day One Biopharmaceuticals’ $184 million initial public offering of 11,500,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Wedbush Securities acted as lead manager for the offering, and J.P. Morgan Securities, Cowen and Company and Piper Sandler acted as joint book-running managers. Day One Biopharmaceuticals, whose securities now trade on the Nasdaq Global Select Market  under the symbol DAWN, is a clinical-stage biopharmaceutical company. Partners Jonie Kondracki, Charlie Kim and Kristin VanderPas led the Cooley team.

Cooley advised the underwriters on Biomea Fusion’s $153 million initial public offering of 9,000,000 shares of common stock. J.P. Morgan Securities, Jefferies and Piper Sandler acted as joint book-running managers for the offering. Biomea Fusion, whose securities now trade on the Nasdaq Global Select Market under the symbol BMEA, is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Partners Charlie Kim, Jonie Kondracki and Kristin VanderPas led the Cooley team.